FDA adcomm votes unanimously in favor of AstraZeneca's preventive mAb for RSV in infants
The FDA’s Antimicrobial Drugs Advisory Committee voted 21-0 in favor of the benefit-risk profile of AstraZeneca’s nirsevimab, a monoclonal antibody intended to prevent respiratory syncytial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
